Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.

Breast cancer research and treatment - 1 Jun 2009

Onitilo Adedayo A, McCarty Catherine A, Wilke Russell A, Glurich Ingrid, Engel Jessica M, Flockhart David A, Nguyen Anne, Li Lang, Mi Deming, Skaar Todd C, Jin Yan

Abstract excerpt

Thromboembolism is a serious complication of tamoxifen therapy in women with breast cancer. Banked DNA from tamoxifen-treated individuals with breast cancer from the Marshfield Clinic Personalized Medicine Research Project, a population-based DNA repository, was tested for association between incidence of tamoxifen-associated thromboembolic events (TTE) and single nucleotide polymorphisms encoding the estrogen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase

Share to Cytochrome P-450 CYP2D6

Share to Receptors, Estrogen

Share to Survival Rate

Share to Tamoxifen

Share to Venous Thromboembolism

Source

Identifiers

PMID: 19082882
DOI: 10.1007/s10549-008-0264-2

Genes

ESR1
ESR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.PMID 19082882Read ↗

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

Invited review: Pharmacogenetics of estrogen replacement therapy.Semantic proximity Read ↗

Tamoxifen-induced venothromboembolic events: exploring validation of putative genetic association.Semantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study.Semantic proximity Read ↗

Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?Semantic proximity Read ↗

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.Semantic proximity Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

Variation in estrogen-related genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.